(NYSE:ABT) announced today that it launched its Amplatzer Talisman patent foramen ovale (PFO) occlusion system in Europe.
PFO is a hole in the heart that doesn’t close following birth. The company designed the Amplatzer Talisman to treat people with PFO who experienced a stroke and are at risk of having another.
Occlusion with the Talisman PFO is a minimally invasive, catheter-based procedure. It seals off the opening to reduce the risk of another stroke.
Abbott Park, Illinois-based Abbott’s new Talisman PFO occluders come pre-attached to the delivery cable. This design reduces preparation time for doctors and increases ease of use.
Manchester England-based cardiologist Matthew Daniels completed the first European procedure with Talisman PFO.
“Guidelines from industry organizations and clinical trial data continue to reinforce the benefits of PFO closure for people who have had a PFO-associated stroke,” Daniels said in a news release. “We’re excited that physicians around Europe now have access to the Talisman device to help reduce patients’ risk and worry of experiencing another stroke.”
Abbott’s Amplatzer Talisman builds off the company’s Amplatzer PFO occluder system. Previously, physicians had to attach it to the delivery cable before implant. However, the Talisman comes pre-assembled with the Amplatzer Trevisio delivery cable.
Talisman also accommodates a range of patient anatomies. It features a 30mm occluder size to optimize fit in the heart. It is also fully recapturable and repositionable for easy adjustments and accurate placement.
“Our trusted PFO closure technology has been used to treat more than 180,000 people worldwide and we haven’t let up on continuing to innovate to best serve physicians and patients,” Michael Dale, SVP of Abbott’s structural heart business, said in the news release. “The Talisman system simplifies the procedure for doctors and helps patients quickly get back to living fuller, healthier lives.”